---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-004220"
form_type: "8-K"
ticker: "ZSQR"
cik: "0001759186"
company_name: "Z Squared Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:59:16.078317+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Coeptis Therapeutics closes $3.5M underwritten offering of common stock and warrants

## Summary
- Offering gross proceeds ~$3.5M before expenses; closed June 16, 2023 to a single healthcare investor.
- Components: 2,150,000 shares, 1,350,000 pre-funded warrants at $0.0001, 3,062,500 Series A and 3,062,500 Series B warrants at $1.65.
- Series A and B warrants exercisable for five years starting six months after issuance; fixed pricing with no resets.
- Ladenburg Thalmann acted as sole book-running manager; lock-up of 75 days for company and insiders.

## SEC filing metadata
- accession: 0001683168-23-004220
- form_type: 8-K
- ticker: ZSQR
- cik: 0001759186
- company_name: Z Squared Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759186/000168316823004220/0001683168-23-004220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759186/000168316823004220/coeptis_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-004220
- JSON: https://secwatch.observer/filing/0001683168-23-004220.json
- Plain text: https://secwatch.observer/filing/0001683168-23-004220.txt

## Key facts
- Material Agreements
  Z Squared Inc. entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at approximately $3.5 million (effective 2023-06-13).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Ladenburg Thalmann & Co. Inc.
  - Value: approximately $3.5 million
  - Effective: 2023-06-13
  source text: On June 13, 2023, Coeptis Therapeutics Holdings, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Underwriter”), pursuant to which the Company issued and sold, in a registered public offering by the Company (the “Offering”) (i) 2,150,000 shares of common stock (the “Shares”), (ii) 1,350,000 pre-funded warrants (the “Pre-funded Warrants”), (iii) 3,062,500 Series A Warrants with an exercise price of $1.65 per share and which are exercisable for a period of five years commencing six months after the issuance date (the “Series A Warrants”), and (iv) 3,062,500 Series B Warrants with an exercise price of $1.65 per share and which are exercisable for a period of five years commencing six months after the issuance date (the “Series B Warrants, and together with the Pre-funded Warrants and the Series B Warrants, the “Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759186/000168316823004220/0001683168-23-004220-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.